BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 33036620)

  • 1. Assessment of EN-RAGE, sRAGE and EN-RAGE/sRAGE as potential biomarkers in patients with autoimmune hepatitis.
    Wu R; Liu Y; Yan R; Liu X; Duan L
    J Transl Med; 2020 Oct; 18(1):384. PubMed ID: 33036620
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduced Circulating Soluble Receptor for Advanced Glycation End-products in Chronic Hepatitis B Are Associated with Hepatic Necroinflammation.
    Zhang X; You Y; Liu Q; Sun X; Chen W; Duan L
    Inflammation; 2022 Dec; 45(6):2559-2569. PubMed ID: 35790658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Higher levels of the soluble receptor for advanced glycation end products and lower levels of the extracellular newly identified receptor for advanced glycation end products were associated with lipid-lowering drugs in patients with type 1 diabetes: a comparative cross-sectional study.
    Melin EO; Dereke J; Hillman M
    Lipids Health Dis; 2020 Oct; 19(1):223. PubMed ID: 33054750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma levels of soluble receptor for advanced glycation end products (sRAGE) and proinflammatory ligand for RAGE (EN-RAGE) are associated with carotid atherosclerosis in patients with peritoneal dialysis.
    Kim JK; Park S; Lee MJ; Song YR; Han SH; Kim SG; Kang SW; Choi KH; Kim HJ; Yoo TH
    Atherosclerosis; 2012 Jan; 220(1):208-14. PubMed ID: 21906738
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of EN-RAGE, sRAGE, and its isoforms: cRAGE, esRAGE in obese patients treated by moderate caloric restriction combined with physical activity conducted in hospital condition.
    Kanikowska D; Kanikowska A; Strojny Z; Kawka E; Zawada A; Rutkowski R; Litwinowicz M; Sato M; Grzymisławski M; Bręborowicz A; Witowski J; Korybalska K
    Cytokine; 2024 Aug; 180():156665. PubMed ID: 38823153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating levels of soluble receptor for advanced glycation end products and ligands of the receptor for advanced glycation end products in patients with acute liver failure.
    Basta G; Del Turco S; Navarra T; Lee WM;
    Liver Transpl; 2015 Jun; 21(6):847-54. PubMed ID: 25825217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma S100A12 and soluble receptor of advanced glycation end product levels and mortality in chronic kidney disease Stage 5 patients.
    Isoyama N; Leurs P; Qureshi AR; Bruchfeld A; Anderstam B; Heimburger O; Bárány P; Stenvinkel P; Lindholm B
    Nephrol Dial Transplant; 2015 Jan; 30(1):84-91. PubMed ID: 25074436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Placental growth factor, pregnancy-associated plasma protein-A, soluble receptor for advanced glycation end products, extracellular newly identified receptor for receptor for advanced glycation end products binding protein and high mobility group box 1 levels in patients with acute kidney injury: a cross sectional study.
    Zakiyanov O; Kriha V; Vachek J; Zima T; Tesar V; Kalousova M
    BMC Nephrol; 2013 Nov; 14():245. PubMed ID: 24188108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum levels of advanced glycation end products (AGEs) are increased and their soluble receptor (sRAGE) reduced in Hashimoto's thyroiditis.
    Ruggeri RM; Barbalace MC; Cristani MT; Alibrandi A; Giovinazzo S; Giuffrida G; Trimarchi F; Cannavò S; Campennì A
    J Endocrinol Invest; 2020 Sep; 43(9):1337-1342. PubMed ID: 32232775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic levels of the anti-inflammatory decoy receptor soluble RAGE (receptor for advanced glycation end products) are decreased in dogs with inflammatory bowel disease.
    Heilmann RM; Otoni CC; Jergens AE; Grützner N; Suchodolski JS; Steiner JM
    Vet Immunol Immunopathol; 2014 Oct; 161(3-4):184-92. PubMed ID: 25183017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum levels of advanced glycation end-products (AGEs) and the decoy soluble receptor for AGEs (sRAGE) can identify non-alcoholic fatty liver disease in age-, sex- and BMI-matched normo-glycemic adults.
    Palma-Duran SA; Kontogianni MD; Vlassopoulos A; Zhao S; Margariti A; Georgoulis M; Papatheodoridis G; Combet E
    Metabolism; 2018 Jun; 83():120-127. PubMed ID: 29409822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histological activity despite normal ALT and IgG serum levels in patients with autoimmune hepatitis and cirrhosis.
    Laschtowitz A; Zachou K; Lygoura V; Pape S; Derben F; Jaeckel E; Oller-Moreno S; Weidemann S; Krech T; Piecha F; Schön G; Liebhoff AM; Al Tarrah M; Heneghan M; Drenth JPH; Dalekos G; Taubert R; Lohse AW; Schramm C
    JHEP Rep; 2021 Aug; 3(4):100321. PubMed ID: 34381983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of circulating soluble receptor for advanced glycation end products (sRAGE) and the proinflammatory RAGE ligand (EN-RAGE, S100A12) on mortality in hemodialysis patients.
    Nakashima A; Carrero JJ; Qureshi AR; Miyamoto T; Anderstam B; Bárány P; Heimbürger O; Stenvinkel P; Lindholm B
    Clin J Am Soc Nephrol; 2010 Dec; 5(12):2213-9. PubMed ID: 20847094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Autoimmune liver diseases and their overlap syndromes].
    Strassburg CP
    Praxis (Bern 1994); 2006 Sep; 95(36):1363-81. PubMed ID: 16989180
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overlap of concurrent extrahepatic autoimmune diseases is associated with milder disease severity of newly diagnosed autoimmune hepatitis.
    Mühling T; Rohrbach H; Schepp W; Gundling F
    Hepatobiliary Pancreat Dis Int; 2021 Feb; 20(1):21-27. PubMed ID: 32830050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of the receptor for advanced glycation end products system in women with severe preeclampsia.
    Oliver EA; Buhimschi CS; Dulay AT; Baumbusch MA; Abdel-Razeq SS; Lee SY; Zhao G; Jing S; Pettker CM; Buhimschi IA
    J Clin Endocrinol Metab; 2011 Mar; 96(3):689-98. PubMed ID: 21325454
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of soluble receptor for advanced glycation end-products (sRAGE) in the general population and patients with diabetes mellitus with a focus on renal function and overall outcome.
    Steenbeke M; De Bruyne S; De Buyzere M; Lapauw B; Speeckaert R; Petrovic M; Delanghe JR; Speeckaert MM
    Crit Rev Clin Lab Sci; 2021 Mar; 58(2):113-130. PubMed ID: 32669010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Receptor for advanced glycation end products (RAGE) soluble form (sRAGE): a new biomarker for lung cancer.
    Jing R; Cui M; Wang J; Wang H
    Neoplasma; 2010; 57(1):55-61. PubMed ID: 19895173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alarmins and Related Molecules in Elective Surgery.
    Strohalmová S; Levová K; Kuběna AA; Hoskovec D; Krška Z; Zima T; Kalousová M
    Folia Biol (Praha); 2023; 69(2):50-58. PubMed ID: 38063001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dysregulation of gastrointestinal RAGE (receptor for advanced glycation end products) expression in dogs with chronic inflammatory enteropathy.
    Cabrera-García AI; Protschka M; Alber G; Kather S; Dengler F; Müller U; Steiner JM; Heilmann RM
    Vet Immunol Immunopathol; 2021 Apr; 234():110216. PubMed ID: 33636544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.